Aquaculture biotechnology company Benchmark Holdings has announced its unaudited interim results for the quarter ending March 31, 2024.
The company reported an operating profit of £0.6 million for the quarter, down slightly from £0.7 million in the same period the previous year.
Benchmark’s turnover for the quarter was £40 million, compared to £44 million in Q2 2023. Adjusted EBITDA stood at £10 million, a decrease from £11 million in the corresponding quarter last year.
As of May 20, 2024, Benchmark Holdings had cash and cash equivalents of £24 million and total available liquidity of £41 million.
“I am pleased with the Company’s performance in the second quarter and the first half as a whole, which demonstrated good momentum in the business supporting our positive outlook. We have delivered strong trading in our established business areas, have made excellent progress in Chile, one of our key growth vectors, and made significant progress in our innovation programme where our recent investment to strengthen our innovation capabilities is bearing fruit,” said Trond Williksen, CEO of Benchmark Holdings.
“With our unique platform of mission-critical specialised solutions in areas where we hold market-leading positions, we are strongly positioned to continue to deliver growth and build sustainable shareholder value.”
